Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative Immunotherapy for Early-stage Non-small-cell Lung Cancer
NCT06572722Phase 2Withdrawn
- Sponsor
- Fudan University
- Start
- Sep 2024
- Primary completion
- Sep 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
01
Overview
A Phase 2 trial of atezolizumab, nivolumab, pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by Fudan University. Planned start Sep 2024; status: withdrawn.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06572722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06572722.